We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on the medicines.ie website. Find out more

Takeda Products Ireland Ltd

First Floor, 3013 Lake Drive, Citywest Business Campus, Dublin 24, Ireland
Telephone: +353 1 642 0021
Fax: +353 1 642 0020
Medical Information Direct Line: 1800 937970
Medical Information e-mail: DSO-UK@takeda.com
Medical Information Facsimile: +44 (0)1628 526 617
Patient Information Leaflet last updated on medicines.ie: 14/07/2017
PIL Matrifen Transdermal Patch

When a pharmaceutical company changes an SPC or PIL, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 14/07/2017 and displayed until Current
Reasons for adding or updating:
  • Change to Section 1 - what the product is
  • Change to section 1 - what the product is used for
  • Change to section 2 - what you need to know - contraindications
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - use in children and adolescents
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 2 - pregnancy, breast feeding and fertility
  • Change to section 2 - driving and using machines
  • Change to section 3 - dose and frequency
  • Change to section 3 - how to take/use
  • Change to section 3 - duration of treatment
  • Change to section 3 - overdose, missed or forgotten doses
  • Change to section 4 - possible side effects
  • Change to section 5 - how to store or dispose
  • Change to section 6 - date of revision
Updated on 06/05/2015 and displayed until 14/07/2017
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change of contraindications
  • Change to side-effects
  • Change to information about drinking alcohol
  • Change to date of revision
  • Change to improve clarity and readability
  • Addition of information on reporting a side effect.
  • Improved electronic presentation
Updated on 02/10/2014 and displayed until 06/05/2015
Reasons for adding or updating:
  • Change to date of revision
  • Change to marketing authorisation holder
Updated on 16/04/2013 and displayed until 02/10/2014
Reasons for adding or updating:
  • Change to marketing authorisation holder
Updated on 25/08/2011 and displayed until 16/04/2013
Reasons for adding or updating:
  • Improved electronic presentation
Updated on 07/07/2011 and displayed until 25/08/2011
Reasons for adding or updating:
  • Change due to harmonisation of PIL
Updated on 27/08/2010 and displayed until 07/07/2011
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 15/01/2009 and displayed until 27/08/2010
Reasons for adding or updating:
  • Improved electronic presentation
Updated on 30/10/2008 and displayed until 15/01/2009
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision
  • Change to dosage and administration
Updated on 21/11/2007 and displayed until 30/10/2008
Reasons for adding or updating:
  • Addition of marketing authorisation holder
Updated on 10/07/2007 and displayed until 21/11/2007
Reasons for adding or updating:
  • New PIL for new product

Document Links

 
  View all medicines
from this company
View Document
Bookmark and Share

Active Ingredients

 
   Fentanyl